ERBB2 and breast carcinoma: Among the 197 breast cancer lesions of 192 patients in the nonmetastatic group, 25 (12.7%) were luminalA type, 134 (68.0%) were luminalB type, 13 (6.6%) were Her-2 overexpression type, and 25 (12.7%) were triple-negative type.